What Mylan Itraconazole Helps Treat: Main Uses and Benefits

The medication is commonly used to help with a range of conditions involving episodic or fluctuating manifestations caused by fungal organisms. The medicine is applied across domains where additional symptomatic support is needed, addressing symptoms that create noticeable physiological strain. It is relevant in clinical settings marked by increased discomfort or tension, addressing symptoms linked to organ-specific functional stress or inflammatory states.

---

Managing Surface Fungal Infections (Dermatomycoses)

This domain covers conditions presenting with systemic or localized discomfort in situations involving certain distressing symptoms related to inflammatory or irritative states. It contributes to improved comfort during periods of heightened symptoms by addressing symptom clusters that may become intense or disruptive to daily functioning. Quick Fact: Supports functional stability during symptomatic periods.

---

Supportive Use in Clinical Settings

The medication may be part of symptomatic management relevant in contexts involving heightened systemic burden and conditions where symptoms may intensify temporarily. It assists with maintaining functional stability when symptoms become more noticeable.

“Applied in contexts where additional symptomatic support for symptom management is needed.”

Regulatory References

1. Health Canada Product Monograph

Mylan Itraconazole is generally indicated for use in adult patients, but eligibility is strictly governed by medical criteria outlined in official regulatory labeling.

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed (as stated in label)	Adult patients who are non-immunocompromised or immunocompromised.
Populations for whom use is not recommended	Pediatric patients (efficacy and safety not established for capsules). Older adults (clinical data limited; use requires caution).
Populations for whom use is contraindicated	Patients with known hypersensitivity to itraconazole. Patients with evidence of ventricular dysfunction such as Congestive Heart Failure or a history of CHF, except for life-threatening infections. Pregnant patients for non-life-threatening indications.
Pregnancy and lactation eligibility status	Pregnancy: Contraindicated for non-life-threatening use. Lactation: Breastfeeding must be discontinued before treatment.

Condition-specific Eligibility Rules

Treatment is strongly discouraged for patients with active liver disease or significantly elevated liver enzymes. Caution is required for patients with renal impairment due to limited data and potential changes in drug exposure. Women of childbearing potential must use effective contraception during and after therapy.

Mylan Itraconazole can interact with many other medicines and products, which may change how the medicine works or increase the risk of serious side effects. These interactions are often due to Itraconazole's effect on a liver enzyme system known as Cytochrome P450 3A4 (CYP3A4), which is responsible for metabolizing many drugs.

️ Contraindicated Medicines

The co-administration of Itraconazole with certain drugs is contraindicated and should be avoided due to the potential for serious or life-threatening reactions, including severe heart rhythm problems (QT prolongation) or increased toxicity. These include, but are not limited to:

Drug Class	Examples of Contraindicated Drugs
Antiarrhythmics	Dofetilide, dronedarone, quinidine
Antihistamines	Terfenadine, astemizole (Note: largely withdrawn from market)
GI Motility Agents	Cisapride
Statins	Lovastatin, simvastatin
Sedatives/Hypnotics	Oral midazolam, triazolam
Ergot Alkaloids	Ergotamine, dihydroergotamine, ergometrine

Other Significant Interactions

Drugs That May Increase Itraconazole Levels: Co-administration with strong CYP3A4 inhibitors (e.g., clarithromycin, certain HIV/AIDS medications) can increase the concentration of Itraconazole in the blood, potentially raising the risk of side effects, including hearing loss or heart failure. Dose adjustments or monitoring may be necessary.

Drugs That May Decrease Itraconazole Levels: Medicines that reduce stomach acid (e.g., antacids, H2 blockers, proton pump inhibitors) can significantly decrease the absorption of Itraconazole capsules, making the treatment less effective. Separate dosing times or use of an acidic beverage (like cola) may be required. Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) can rapidly decrease Itraconazole concentrations, leading to treatment failure.

Drugs Whose Levels May Be Increased By Itraconazole: Itraconazole may increase the blood levels of many other drugs metabolized by CYP3A4, such as certain calcium channel blockers, anticoagulants (e.g., warfarin), immunosuppressants (e.g., cyclosporine, tacrolimus), and some anticancer agents. This increased exposure can lead to toxicity of the co-administered drug. Careful monitoring and dosage reduction are often required.

How Mylan Itraconazole Works

---

Selective Fungal Enzyme Inhibition

Itraconazole's mechanism begins with its selective inhibition of lanosterol 14alpha-demethylase (CYP51), a cytochrome P450 enzyme essential to the fungal organism. The drug achieves this by coordinating with the heme iron of the enzyme, physically blocking the catalytic site and preventing a critical metabolic step. This inhibition is sustained by the drug's main metabolite, hydroxyitraconazole, which has comparable antifungal activity and contributes to the overall mechanistic effect.

Disruption of Ergosterol Biosynthesis and Cell Integrity

By blocking CYP51, the drug halts the synthesis of ergosterol, which is the primary sterol that maintains the structural integrity and fluidity of the fungal cell membrane. This causes the simultaneous accumulation of toxic 14-methylated sterol intermediates. The resulting defective membrane structure leads to increased permeability and leakage of cellular contents, culminating in a fungistatic or fungicidal effect, which results in the elimination of the fungal organism.

Constraints on Mechanism's Efficacy

The mechanism's efficacy is biologically constrained by two main factors: acquired fungal resistance and tissue penetration. Fungi can reduce the drug's potency by developing mutations in the CYP51 enzyme or by increasing the activity of efflux pump proteins that actively transport the drug out of the cell. Furthermore, the drug achieves low concentrations in the Cerebrospinal Fluid (CSF), restricting the mechanism's physiological reach in the central nervous system.

Instructions for Administration and Dosing

Mylan Itraconazole is administered via the oral route in capsule, tablet, or oral solution forms. The correct method of intake—particularly in relation to food—is critical and defined by the specific formulation to ensure proper absorption:

• Capsules and Tablets: Must be taken immediately after a full meal and should be swallowed whole.
• Oral Solution: Must be taken on an empty stomach or approximately one hour after eating. For treating oral candidiasis, the solution should be swished around the mouth for about 20 seconds before swallowing.

---

Standard Dosing and Schedule Patterns

The required dosing frequency and duration vary significantly by the condition being addressed:

Regimen Feature	Standard Guideline (Capsules/Tablets)
Loading Dose (Systemic Infections)	200 mg three times daily for the first 3 days.
Maintenance Dose (Systemic Infections)	200 mg to 400 mg per day, given as a single or divided dose.
Pulse Dosing (Onychomycosis)	200 mg twice daily for 1 week (a pulse), separated by a 3-week drug-free interval.

For continuous regimens, treatment may extend for several weeks up to twelve consecutive weeks, or longer for systemic infections. If a dose is missed, the general practice is to take the next dose at the regularly scheduled time and not double the dose.

Special Procedural Constraints

The capsule and oral solution forms are not interchangeable due to differences in absorption. Furthermore, patients with impaired hepatic or renal function require careful monitoring during administration.

Mylan Itraconazole: Recent Clinical Evidence

This section outlines the research evidence available for Itraconazole (generic, including the Mylan brand), examining study findings in key therapeutic areas.

---

Core Clinical Trials: Evaluating Antifungal Outcomes

Several large-scale, double-blind, randomized controlled trials (RCTs) have evaluated Itraconazole for use in various fungal infections, including Onychomycosis and systemic candidiasis. Itraconazole belongs to the class of triazole antifungals, which inhibit a fungal enzyme necessary for cell membrane production.

• Onychomycosis Findings: Studies evaluating pulse dosing regimens indicated data points relating to clinical and mycological resolution rates in the participant population.
• Systemic Infection Data: Research observed that the administration of Itraconazole was associated with changes in infection markers in patients with certain systemic mycoses.

---

Pharmacokinetics and Administration Profile

Itraconazole's absorption is highly variable and is influenced by gastric acidity. Research has focused on understanding the bioavailability differences between the capsule and oral solution formulations.

Formulation Type	Bioavailability Characteristic	Research Focus
Capsules	Requires acidic environment for optimal absorption.	Effect of food on absorption and resulting plasma concentrations.
Oral Solution	Better absorption when administered without food.	Plasma concentration monitoring in immunocompromised patients.

---

Adverse Event Review

Long-term studies have examined the administration of Itraconazole. The research documented the incidence of common and serious adverse events (AEs) over the study period. The most frequently reported AEs in research included gastrointestinal disturbances (such as nausea and abdominal pain) and headache. Potential for hepatotoxicity and certain drug interactions necessitates monitoring, as noted in clinical research.

Common questions about Mylan Itraconazole (FAQ)

Q: Does Mylan Itraconazole carry a specific Black Box Warning issued by regulatory bodies?

A: Yes, regulatory documents state that Mylan Itraconazole carries an official Boxed Warning (also known as a Black Box Warning). This warning highlights the risk of Congestive Heart Failure and the potential for serious, even life-threatening, drug interactions that can occur when taken with certain other medicines.

Q: Why is Mylan Itraconazole typically not used as a first-line treatment for all fungal infections?

A: It is generally not considered a first-choice treatment option for all fungal infections because of its risk profile. Regulatory documents highlight the potential for serious side effects like heart failure and liver problems, as well as the drug’s high potential for drug interactions with many other medications.

Q: Can Mylan Itraconazole interact with common blood pressure medications?

A: Official product information indicates that the drug has been associated with reports of increased blood pressure (hypertension) as a side effect. It is also important to know that the drug is contraindicated (should not be taken) with certain heart-rhythm medications because of the risk of serious cardiac events. Referencing the official prescribing information can provide a comprehensive list of drug interactions.

Q: Is Mylan Itraconazole a generic version of another brand-name drug?

A: The active ingredient in this medication is itraconazole, which is the generic name. Regulatory documents and drug information sources confirm that itraconazole is also found in brand-name products such as Sporanox and Tolsura. Mylan is the manufacturer of the generic version of the active ingredient, itraconazole.

Q: Why is Mylan Itraconazole classified as a broad-spectrum antifungal medication?

A: Official information describes this medication as a broad-spectrum antifungal. This classification is due to its confirmed activity against a wide range of fungi, including Aspergillus, Blastomyces, Histoplasma, and various Candida species.

Q: How long does it usually take for Mylan Itraconazole to show an effect?

A: According to official pharmacokinetic studies, the drug is slowly absorbed by the body. Steady-state concentrations are typically reached within about 15 days of starting treatment. Steady-state refers to the point where the medication has accumulated enough in the body to reach the level needed for its full therapeutic effect.

Q: How is Mylan Itraconazole chemically or functionally different from fluconazole?

A: Regulatory and drug summary sources indicate that Itraconazole generally has a broader spectrum of antifungal activity than fluconazole. This functional difference means Itraconazole is effective against certain pathogens, such as Aspergillus species, that fluconazole is not.

Q: Is Mylan Itraconazole known to interact with common birth control pills?

A: Official prescribing information contains statements regarding the required use of effective contraception by women of childbearing potential during treatment. This is also required for a period of at least 2 months after the last dose has been taken. This instruction is related to the possibility of the drug potentially causing harm to an unborn baby.

Q: Are there any known interactions between Mylan Itraconazole and widely available herbal supplements?

A: Official drug labeling advises patients to inform their health provider about all medications they take, which includes prescription, over-the-counter medicines, and herbal products. This is because not all possible interactions can be comprehensively listed in the drug label.

Q: Can Mylan Itraconazole be used to treat common vaginal yeast infections?

A: Yes, the official indications for Itraconazole include the treatment of vulvo-vaginal candidiasis. This is a specific type of yeast infection that the medication is approved to address.

Q: Can Mylan Itraconazole affect a person's mood or potentially cause anxiety?

A: According to official sources that document adverse reactions, side effects that have been reported include mood changes and feelings of nervousness. Patients should be aware of these potential effects as described in the product information.

Q: What specific types of fungal infections is Mylan Itraconazole NOT effective against?

A: Official documents caution that the drug achieves very low concentrations in the Cerebrospinal Fluid (CSF). Because of this, it is generally not recommended for use against meningitis or other fungal infections located in the central nervous system.

Q: How long does Mylan Itraconazole typically stay in a person's system after they stop taking it?

A: Pharmacokinetic studies indicate that after a person stops treatment, the drug's concentration in the plasma (blood) generally decreases to an almost undetectable level within 7 to 14 days. This clearance time is expected but can depend on the dose and duration of the therapy.

Q: Is Mylan Itraconazole included on the World Health Organization's essential medicines list?

A: The active ingredient in this medication, itraconazole, is included on the World Health Organization's (WHO) Essential Medicines List. This list recognizes it as one of the most effective and safe medicines needed in a basic health system.

Q: Is Mylan Itraconazole known to cause or contribute to hair loss?

A: Official product information documenting adverse events indicates that hair loss has been reported as a side effect associated with the use of this medication.

Q: Are there specific lab tests needed before starting Mylan Itraconazole?

A: Due to the drug's association with rare cases of serious hepatotoxicity (liver injury), official safety restrictions state that monitoring of liver function should be considered. This monitoring is typically carried out both before starting and during the course of treatment, according to safety guidelines.

Q: Can Mylan Itraconazole cause sensitivity to the sun?

A: Official adverse reaction documents indicate that increased sensitivity to sunlight, also known as photosensitivity, has been reported as a side effect. Regulatory documents indicate that patients taking this medication are generally advised to be mindful of this potential effect.

Q: What is the function of the cyclodextrin component sometimes used in Itraconazole formulations?

A: According to the composition details in regulatory documents, cyclodextrins are used as an inactive ingredient in the oral solution formulation. Their purpose is to increase the drug's solubility and enhance its absorption into the body.

Q: Are there any restrictions on driving or operating heavy machinery while taking Mylan Itraconazole?

A: Official safety information advises that the possibility of certain side effects must be taken into account before driving or operating heavy machinery. These reported side effects include dizziness, visual disturbances, and hearing loss.

Official Storage and Disposal Requirements

Itraconazole capsules must be stored at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F). Storage areas must be kept cool and dry, and the medicine requires protection from light and moisture.

Storage Restriction	Requirement
Temperature Range	20°C to 25°C
Protection	Guard from light, moisture, and excessive heat (do not store in bathrooms)
Container	Must be kept in the original container, tightly closed
Child Safety	Must be kept out of the sight and reach of children

Unused or expired itraconazole should not be discarded in the trash or poured into wastewater systems. Disposal must follow official procedures, such as using a drug take-back program or adhering to specific government guidelines for safe household disposal.